Shattuck Labs (NASDAQ:STTK) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Shattuck Labs (NASDAQ:STTK) announced its earnings results on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.01, Zacks reports. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK opened at $1.14 on Friday. The business’s 50 day simple moving average is $1.25 and its 200 day simple moving average is $1.51. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76. The company has a market capitalization of $54.42 million, a P/E ratio of -0.75 and a beta of 1.66.

Wall Street Analysts Forecast Growth

STTK has been the topic of several recent research reports. Leerink Partnrs raised shares of Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a research report on Thursday. HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a research note on Thursday. Finally, Leerink Partners initiated coverage on Shattuck Labs in a report on Monday, March 17th. They issued an “outperform” rating and a $4.00 target price on the stock. Four analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.